The diagnosis and treatment of acute and chronic leukemia are changing dramatically. In recent years, numerous new drugs have entered the market, changing the prognosis of leukemia patients. In this context, a continuous exchange among peers, together with the opportunity to hear the most important news from the voices of Europe's leading key opinion leaders, is essential to ensure the best level of care for leukemia patients.
The all-new format will feature debate-style presentations on hot topics in acute and chronic leukemia, with speakers presenting contrasting views to stimulate interactive discussion with faculty and attendees. Euroleuk2023 will continue to provide clinicians and biologists with the latest recommendations for patient care, as well as insights into controversies and new therapeutic perspectives in the field.
URLs:
Tickets: https://go.evvnt.com/1724008-0?pid=10297
Website: https://go.evvnt.com/1724008-3?pid=10297
Brochure: https://go.evvnt.com/1724008-4?pid=10297
Date and Time: On Mon, Nov 20, 2023 ( 8:00 AM) - Tue, Nov 21, 2023 ( 5:00 PM)
Category: Conferences | Science, Health and Medicine | CME (Continuing Medical Education)
Prices:
Physicians Early Registration until 18 August 2023: EUR 350.00,
Physicians Regular Registration 19 August - 28 September 2023: EUR 450.00,
Physicians late Registration 29 September - 19 November 2023: EUR 550.00,
Industry Early Registration until 18 August 2023: EUR 700.00,
Industry Regular Registration 19 Aug-28 Sept 2023: EUR 850.00,
Industry Late Registration 29 Sept-19 Nov 2023: EUR 980.00,
Student/Resident of Developing country - Early Reg: EUR 200.00,
Student/Resident of Developing country - Regular Reg: EUR 280.00,
Student/Resident of Developing country - Late Reg: EUR 360.00
Speakers: Thomas Cluzeau, Centre Hospitalier Universitaire de Nice (CHU de Nice), France, Adolfo de la Fuente Burguera, MD Anderson Cancer Center Madrid, Spain, Yngvar Floisand, University of Oslo, Norway, Klaus Metzeler, University of Leipzig, Germany, Oliver Ottman, Cardiff University, UK, Alessandro Isidori, March Nord Hospital Pesaro, Italy